Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Tulisokibart met its primary endpoint of clinical remission at 12 weeks in Phase 3 trial for ulcerative colitis.
Asset / Drug
Drug and asset intelligence for Tulisokibart with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.